BACKGROUND: Autism spectrum disorder (ASD) is behaviorally and biologically heterogeneous and likely represents a series of conditions arising from different underlying genetic, metabolic, and environmental factors. There are currently no reliable diagnostic biomarkers for ASD. Based on evidence that dysregulation of branched-chain amino acids (BCAAs) may contribute to the behavioral characteristics of ASD, we tested whether dysregulation of amino acids (AAs) was a pervasive phenomenon in individuals with ASD. This is the first article to report results from the Children's Autism Metabolome Project (CAMP), a large-scale effort to define autism biomarkers based on metabolomic analyses of blood samples from young children. METHODS: Dysregulation of AA metabolism was identified by comparing plasma metabolites from 516 children with ASD with those from 164 age-matched typically developing children recruited into the CAMP. ASD subjects were stratified into subpopulations based on shared metabolic phenotypes associated with BCAA dysregulation. RESULTS: We identified groups of AAs with positive correlations that were, as a group, negatively correlated with BCAA levels in ASD. Imbalances between these two groups of AAs identified three ASD-associated amino acid dysregulation metabotypes. The combination of glutamine, glycine, and ornithine amino acid dysregulation metabotypes identified a dysregulation in AA/BCAA metabolism that is present in 16.7% of the CAMP subjects with ASD and is detectable with a specificity of 96.3% and a positive predictive value of 93.5% within the ASD subject cohort. CONCLUSIONS: Identification and utilization of metabotypes of ASD can lead to actionable metabolic tests that support early diagnosis and stratification for targeted therapeutic interventions.
BACKGROUND:Autism spectrum disorder (ASD) is behaviorally and biologically heterogeneous and likely represents a series of conditions arising from different underlying genetic, metabolic, and environmental factors. There are currently no reliable diagnostic biomarkers for ASD. Based on evidence that dysregulation of branched-chain amino acids (BCAAs) may contribute to the behavioral characteristics of ASD, we tested whether dysregulation of amino acids (AAs) was a pervasive phenomenon in individuals with ASD. This is the first article to report results from the Children's Autism Metabolome Project (CAMP), a large-scale effort to define autism biomarkers based on metabolomic analyses of blood samples from young children. METHODS: Dysregulation of AA metabolism was identified by comparing plasma metabolites from 516 children with ASD with those from 164 age-matched typically developing children recruited into the CAMP. ASD subjects were stratified into subpopulations based on shared metabolic phenotypes associated with BCAA dysregulation. RESULTS: We identified groups of AAs with positive correlations that were, as a group, negatively correlated with BCAA levels in ASD. Imbalances between these two groups of AAs identified three ASD-associated amino acid dysregulation metabotypes. The combination of glutamine, glycine, and ornithine amino acid dysregulation metabotypes identified a dysregulation in AA/BCAA metabolism that is present in 16.7% of the CAMP subjects with ASD and is detectable with a specificity of 96.3% and a positive predictive value of 93.5% within the ASD subject cohort. CONCLUSIONS: Identification and utilization of metabotypes of ASD can lead to actionable metabolic tests that support early diagnosis and stratification for targeted therapeutic interventions.
Authors: Timothy Buie; Daniel B Campbell; George J Fuchs; Glenn T Furuta; Joseph Levy; Judy Vandewater; Agnes H Whitaker; Dan Atkins; Margaret L Bauman; Arthur L Beaudet; Edward G Carr; Michael D Gershon; Susan L Hyman; Pipop Jirapinyo; Harumi Jyonouchi; Koorosh Kooros; Rafail Kushak; Pat Levitt; Susan E Levy; Jeffery D Lewis; Katherine F Murray; Marvin R Natowicz; Aderbal Sabra; Barry K Wershil; Sharon C Weston; Lonnie Zeltzer; Harland Winter Journal: Pediatrics Date: 2010-01 Impact factor: 7.124
Authors: Heather Cody Hazlett; Hongbin Gu; Brent C Munsell; Sun Hyung Kim; Martin Styner; Jason J Wolff; Jed T Elison; Meghan R Swanson; Hongtu Zhu; Kelly N Botteron; D Louis Collins; John N Constantino; Stephen R Dager; Annette M Estes; Alan C Evans; Vladimir S Fonov; Guido Gerig; Penelope Kostopoulos; Robert C McKinstry; Juhi Pandey; Sarah Paterson; John R Pruett; Robert T Schultz; Dennis W Shaw; Lonnie Zwaigenbaum; Joseph Piven Journal: Nature Date: 2017-02-15 Impact factor: 49.962
Authors: Dora C Tărlungeanu; Elena Deliu; Christoph P Dotter; Majdi Kara; Philipp Christoph Janiesch; Mariafrancesca Scalise; Michele Galluccio; Mateja Tesulov; Emanuela Morelli; Fatma Mujgan Sonmez; Kaya Bilguvar; Ryuichi Ohgaki; Yoshikatsu Kanai; Anide Johansen; Seham Esharif; Tawfeg Ben-Omran; Meral Topcu; Avner Schlessinger; Cesare Indiveri; Kent E Duncan; Ahmet Okay Caglayan; Murat Gunel; Joseph G Gleeson; Gaia Novarino Journal: Cell Date: 2016-12-01 Impact factor: 66.850
Authors: Joseph C Boktor; Mark D Adame; Destanie R Rose; Cynthia M Schumann; Karl D Murray; Melissa D Bauman; Milo Careaga; Sarkis K Mazmanian; Paul Ashwood; Brittany D Needham Journal: Mol Psychiatry Date: 2022-08-26 Impact factor: 13.437
Authors: Brittany D Needham; Mark D Adame; Gloria Serena; Destanie R Rose; Gregory M Preston; Mary C Conrad; A Stewart Campbell; David H Donabedian; Alessio Fasano; Paul Ashwood; Sarkis K Mazmanian Journal: Biol Psychiatry Date: 2020-10-10 Impact factor: 13.382
Authors: Sergio Modafferi; Xiali Zhong; Andre Kleensang; Yohei Murata; Francesca Fagiani; David Pamies; Helena T Hogberg; Vittorio Calabrese; Herbert Lachman; Thomas Hartung; Lena Smirnova Journal: Environ Health Perspect Date: 2021-07-14 Impact factor: 9.031